

## **Guideline for the Management of patients with Regular Narrow-Complex Tachyarrhythmia**

This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the circumstances of the individual patient in consultation with the patient and /or carer. Health care professionals must be prepared to justify any deviation from this guidance.

### **Introduction**

This guideline covers the management of patients presenting to hospital with regular narrow complex tachycardias, commonly referred to as supraventricular tachycardias (SVTs).

### **This guideline is for use by the following staff groups :**

Emergency department medical staff  
Acute medical unit medical staff  
Cardiology medical staff

### **Lead Clinician(s)**

Dr W Foster

Consultant Cardiologist

Approved by Cardiology Directorate Committee on: 9<sup>th</sup> October 2024

Review Date: 9<sup>th</sup> October 2027

This is the most current document and is to be used until a revised version is available

**Key amendments to this guideline**

<b>Date</b>	<b>Amendment</b>	<b>Approved by:</b>
20/5/15	Introduction summary added	
20/5/15	Staff groups to use added	
20/5/15	Dr French added to text as arrhythmia specialist	
20/5/15	Minor changes to text to improve clarity	
20/5/15	Audit standards (monitoring tools) added	
August 2017	Document extended for 12 months as per TMC paper approved on 22 <sup>nd</sup> July 2015	TMC
December 2017	Sentence added at the request of the Coroner	
June 2018	Document extended for 3 months as per TLG recommendation	TLG
October 2018	Document reviewed with no changes	Dr Aldhoon
5th Jan 2021	Document extended by 12 months in line with amendment to Key Documents Policy	Dr W Foster
26 <sup>th</sup> August 2021	Document reviewed with no changes and extended by 12 months in line with amendment to Key Documents Policy	Dr Ammar
4 <sup>th</sup> October 2021	Document approved for 3 years	Cardiology Directorate Meeting
9 <sup>th</sup> October 2024	Document approved with no clinical changes	Dr Ammar

# Guideline for the management of patients With regular narrow-complex tachyarrhythmia

## Introduction

Most regular narrow-complex tachyarrhythmia (NCT) is due to:

- atrioventricular nodal re-entry tachycardia (AVNRT)
- atrioventricular re-entry tachycardia (AVRT) due to Wolf-Parkinson-White syndrome
- atrial flutter with 2 to 1 block (or occasionally 1 to 1 conduction),
- atrial tachycardia

In some patients vagal manoeuvres (For example: carotid sinus massage, CSM; Valsalva) will terminate AVNRT and AVRT and may demonstrate the rhythm but not terminate atrial flutter or atrial tachycardia.

In almost all patients intravenous adenosine will terminate AVNRT and AVRT and will demonstrate the rhythm but not terminate it in atrial flutter / atrial tachycardia.

Severely compromised patients may require emergency cardioversion but it is reasonable to attempt to terminate the arrhythmia with CSM or adenosine whilst preparing for DCCV.

## Patients Covered

All patients with regular narrow-complex tachyarrhythmia.

## Guideline

1. Assess the patient.
2. If the patient is pulseless (i.e. in cardiac arrest – heart rate usually >250 per minute) perform **immediate** synchronised cardioversion and follow standard cardiac arrest guidelines.
3. Otherwise, record appropriate history.  
Clinical examination: record heart rate, BP, signs of heart failure or lung disease?  
Unless the patient is severely compromised, record a good quality 12-lead ECG and label with the patient's identity, date and time.  
If the patient is compromised, make preparations for DC cardioversion (For example: call for anaesthetics support).
4. Attach a 12-lead ECG machine (unless this will lead to excessive delay in a compromised patient). **Whilst recording a multi-lead ECG rhythm strip** apply carotid sinus massage (CSM), unless contraindicated by the presence of a carotid bruit or history of documented carotid artery disease.
5. If the arrhythmia is terminated by CSM, record 12-lead ECG in sinus rhythm and refer to arrhythmia clinic for advice on the need for further investigation or treatment
6. If carotid sinus massage demonstrates underlying atrial flutter or atrial tachycardia refer to guideline for the management of atrial fibrillation and atrial flutter.
7. If the arrhythmia persists despite carotid sinus massage, give adenosine 6 mg intravenously as a rapid bolus, **whilst recording a continuous multi-lead rhythm strip**. If this has no effect give 12 mg adenosine as a rapid bolus whilst recording a multi-lead rhythm strip. Note that asthma / COPD is listed as a contra-indication to

adenosine use in the BNF; however in many cases it is safe but use clinical judgement (for example, consider the severity of the airways disease, whether the patient is currently wheezy, and consider the relative safety of alternative strategies). Consult with a senior clinician before administering adenosine to a patient with airways disease.

8. If adenosine terminates the arrhythmia, record a 12-lead ECG in sinus rhythm and refer to arrhythmia clinic for advice on the need for further investigation and treatment. If adenosine demonstrates underlying atrial flutter or atrial tachycardia refer to guideline for the management of atrial fibrillation and atrial flutter.
9. If the arrhythmia persists despite CSM and adenosine and there was no change in heart rate with adenosine, demonstrating underlying atrial flutter or other atrial tachycardia, check the ECG again to ensure that this is not a broad complex tachyarrhythmia (i.e. ventricular tachycardia), in which case refer to guideline for that condition.
10. Next check the patient again: are there high-risk features? Systolic BP less than 90 mm Hg? Heart rate greater than 180? Continuing chest pain? Clinically overt heart failure? If so **seek expert help** to proceed to synchronised cardioversion. If successful reassess patient and record 12-lead ECG in sinus rhythm. Refer for urgent in-patient cardiology assessment.
11. If arrhythmia persists or recurs after attempted cardioversion (3 shocks), **discuss with on call cardiologist** and consider intravenous amiodarone 300 mg over 20-120 minutes, followed by 900 mg over 24 hours. Amiodarone should be given by central venous cannula; alternatives include long lines or drum catheters. Refer for urgent in-patient cardiology assessment.
12. If there are no high-risk features **seek expert help**. Options include intravenous beta blockers or verapamil.
13. If these treatments restores sinus rhythm record 12-lead ECG. If the patient is well enough to be discharged, refer to arrhythmia clinic (dictate letter to Dr Will Foster) and **enclose ECGs** in arrhythmia as well as sinus rhythm.
14. When patients present with a regular NCT that has been documented in the community or in the ambulance but that resolves spontaneously, assess the patient. If they are well enough to be discharged, refer to the arrhythmia clinic for advice on the need for further investigation and treatment (dictate letter to Dr Will Foster), including a copy of both the arrhythmia and subsequent ECG.
15. If the serum K<sup>+</sup> is less than 4.0 mmol/l give potassium replacement therapy. If the arrhythmia persists, despite treatment as in the guidelines above, give intravenous potassium chloride and intravenous magnesium sulphate. If the arrhythmia resolves and the patient is stable, oral potassium replacement is usually adequate.
16. If the patient is well and is discharged from hospital before seeing a member of the cardiology team, give the patient photocopies of their ECG during the arrhythmia, ECG showing termination by CSM or adenosine, and ECG after arrhythmia termination. If cardiology opinion is required please refer to the arrhythmia clinic (dictate letter to Dr Will Foster and enclose ECGs).

## WAHT-CAR-040

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

### Monitoring Tool

This should include realistic goals, timeframes and measurable outcomes.

How will monitoring be carried out?


Who will monitor compliance with the guideline?

Page/ Section of Key Document	Key control:	Checks to be carried out to confirm compliance with the policy:	How often the check will be carried out:	Responsible for carrying out the check:	Results of check reported to: <i>(Responsible for also ensuring actions are developed to address any areas of non-compliance)</i>	Frequency of reporting:
	<b>WHAT?</b>	<b>HOW?</b>	<b>WHEN?</b>	<b>WHO?</b>	<b>WHERE?</b>	<b>WHEN?</b>
	Amiodarone given by central line	Audit of amiodarone use	Annually	Dr W Foster	Directorate audit meeting	Annually
	Referrals have appropriate ECGs enclosed	Audit of referrals to clinic	Annually	Dr W Foster	Directorate audit meeting	Annually

**References**

- Blomstrom-Lundqvist C et al. ACC/AHA/ESC Guidelines for the Management of Patients with Supraventricular Arrhythmias. [www.escardio.org](http://www.escardio.org)

**Regular narrow complex tachycardia**



## CONTRIBUTION LIST

### Key individuals involved in developing the document

Name	Designation
Dr Will Foster	Consultant cardiologist

### Circulated to the following individuals for comments

Name	Designation
Tony Scriven	Consultant Cardiologist
Dzifa Abban	Consultant Cardiologist
Jasper Trevelyan	Consultant Cardiologist
Helen Routledge	Consultant Cardiologist
Imran Ahmad	Consultant Cardiologist
Dave Smith	Consultant Cardiologist
Mike Zairis	Consultant Cardiologist
Rose Johnson	Consultant, Emergency Department, WRH
James France	Consultant, Emergency Department, WRH
David Jenkins	Acute Physician
Miguel Marimon	Acute Physician
Jane Savage	CCU sister
Clare Alexander	CCU sister



**Supporting Document 1 - Equality Impact Assessment Tool**

To be completed by the key document author and included as an appendix to key document when submitted to the appropriate committee for consideration and approval.

Please complete assessment form on next page;



**Worcestershire  
Acute Hospitals**  
NHS Trust



**Herefordshire & Worcestershire STP - Equality Impact Assessment (EIA) Form**  
Please read EIA guidelines when completing this form

**Section 1 - Name of Organisation** (please tick)

Herefordshire & Worcestershire STP		Herefordshire Council		Herefordshire CCG	
Worcestershire Acute Hospitals NHS Trust	x	Worcestershire County Council		Worcestershire CCGs	
Worcestershire Health and Care NHS Trust		Wye Valley NHS Trust		Other (please state)	

<b>Name of Lead for Activity</b>	<b>Dr Ammar/ Dr Will Foster</b>
----------------------------------	---------------------------------

<b>Details of individuals completing this assessment</b>	<b>Name</b>	<b>Job title</b>	<b>e-mail contact</b>
<b>Date assessment completed</b>	<b>05/11/2021</b>		

**Section 2**

Activity being assessed (e.g. policy/procedure, document, service redesign, policy, strategy etc.)	<b>Title:</b> Guideline for the Management of patients with Regular Narrow-Complex Tachyarrhythmia		
What is the aim, purpose and/or intended outcomes of this Activity?	See body of document		
Who will be affected by the development & implementation of this activity?	<input type="checkbox"/> Service User <input checked="" type="checkbox"/> Patient <input type="checkbox"/> Carers <input type="checkbox"/> Visitors	<input type="checkbox"/> Staff <input type="checkbox"/> Communities <input type="checkbox"/> Other _____	

Is this:	<input checked="" type="checkbox"/> Review of an existing activity <input type="checkbox"/> New activity <input type="checkbox"/> Planning to withdraw or reduce a service, activity or presence?
What information and evidence have you reviewed to help inform this assessment? (Please name sources, eg demographic information for patients / services / staff groups affected, complaints etc.)	See body of document
Summary of engagement or consultation undertaken (e.g. who and how have you engaged with, or why do you believe this is not required)	See body of document
Summary of relevant findings	See body of document

**Section 3**

Please consider the potential impact of this activity (during development & implementation) on each of the equality groups outlined below. **Please tick one or more impact box below for each Equality Group and explain your rationale.** Please note it is possible for the potential impact to be both positive and negative within the same equality group and this should be recorded. Remember to consider the impact on e.g. staff, public, patients, carers etc. in these equality groups.

<b>Equality Group</b>	<b>Potential positive impact</b>	<b>Potential neutral impact</b>	<b>Potential negative impact</b>	<b>Please explain your reasons for any potential positive, neutral or negative impact identified</b>
<b>Age</b>				No impact
<b>Disability</b>				No impact
<b>Gender Reassignment</b>				No impact
<b>Marriage &amp; Civil Partnerships</b>				No impact
<b>Pregnancy &amp; Maternity</b>				No impact
<b>Race including Traveling Communities</b>				No impact
<b>Religion &amp; Belief</b>				No impact
<b>Sex</b>				No impact
<b>Sexual Orientation</b>				No impact

Equality Group	Potential <u>positive</u> impact	Potential <u>neutral</u> impact	Potential <u>negative</u> impact	Please explain your reasons for any potential positive, neutral or negative impact identified
<b>Other Vulnerable and Disadvantaged Groups</b> (e.g. carers; care leavers; homeless; Social/Economic deprivation, travelling communities etc.)				No impact
<b>Health Inequalities</b> (any preventable, unfair & unjust differences in health status between groups, populations or individuals that arise from the unequal distribution of social, environmental & economic conditions within societies)				No impact

**Section 4**

What actions will you take to mitigate any potential negative impacts?	Risk identified	Actions required to reduce / eliminate negative impact	Who will lead on the action?	Timeframe
<b>How will you monitor these actions?</b>	N/A			
<b>When will you review this EIA?</b> (e.g in a service redesign, this EIA should be revisited regularly throughout the design & implementation)				

**Section 5** - Please read and agree to the following Equality Statement

**1. Equality Statement**

1.1. All public bodies have a statutory duty under the Equality Act 2010 to set out arrangements to assess and consult on how their policies and functions impact on the 9 protected characteristics: Age; Disability; Gender Reassignment; Marriage & Civil Partnership; Pregnancy & Maternity; Race; Religion & Belief; Sex; Sexual Orientation

1.2. Our Organisations will challenge discrimination, promote equality, respect human rights, and aims to design and implement services, policies and measures that meet the diverse needs of our service, and population, ensuring that none are placed at a disadvantage over others.

1.3. All staff are expected to deliver services and provide services and care in a manner which respects the individuality of service users, patients, carer's etc, and as such treat them and members of the workforce respectfully, paying due regard to the 9 protected characteristics.

<b>Signature of person completing EIA</b>	
<b>Date signed</b>	05/11/2021
<b>Comments:</b>	Completed on behalf of document owners
<b>Signature of person the Leader Person for this activity</b>	
<b>Date signed</b>	
<b>Comments:</b>	



## Supporting Document 2 – Financial Impact Assessment

To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval.

	<b>Title of document:</b>	<b>Yes/No</b>
1.	Does the implementation of this document require any additional Capital resources	No
2.	Does the implementation of this document require additional revenue	No
3.	Does the implementation of this document require additional manpower	No
4.	Does the implementation of this document release any manpower costs through a change in practice	No
5.	Are there additional staff training costs associated with implementing this document which cannot be delivered through current training programmes or allocated training times for staff	No
	Other comments:	

If the response to any of the above is yes, please complete a business case and which is signed by your Finance Manager and Directorate Manager for consideration by the Accountable Director before progressing to the relevant committee for approval